The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)

Hormones

Volumn 17, Issue 2, 2018, Pages 219-229

  Iogna Prat, Laura ^a   Tsochatzis, Emmanuel A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

HCC; Liraglutide; Metformin; Pioglitazone; Steatohepatitis

Indexed keywords

ACARBOSE; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; ELAFIBRANOR; EMPAGLIFLOZIN; ERTUGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LOBEGLITAZONE; METFORMIN; MIGLITOL; PIOGLITAZONE; ROSIGLITAZONE; SAROGLITAZAR; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SOTAGLIFLOZIN; VILDAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

DRUG EFFECT; DRUG EFFICACY; HUMAN; INSULIN TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY;

HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; METFORMIN; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES;

EID: 85049848920     PISSN: 11093099     EISSN: 25208721     Source Type: Journal    
DOI: 10.1007/s42000-018-0021-9     Document Type: Review

References (117)

1. Festi D, Schiumerini R, Marasco G et al (2015) Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Rev Gastroenterol Hepatol 9:1039–1053
2. European association for the study of the liver, European association for the study of diabetes, and European association for the study of obesity (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402
3. Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609
4. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:S17–S29
5. Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654
6. Marengo A, Jouness RI, Bugianesi E (2016) Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis 20:313–324
7. Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397 e310
8. Ekstedt M, Hagstrom H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–1554
9. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285
10. Younossi ZM, Koening AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84
11. Bellentani S (2017) The epidemiology of non-alcoholic fatty liver disease. Liver Int 37(Suppl 1):81–84
12. Wong RJ, Aguilar M, Cheung R et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:547–555
13. McCullough AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12:333–340
14. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation 120:1640–1645
15. Ryan MC, Wilson A, Slavin J et al (2005) Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 28:1222–1224
16. Hamaguchi M, Kojima T, Takeda N et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728
17. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923
18. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A (2016) The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 46:1074–1087
19. Tsochatzis E, Papatheodoridis GV, Manesis EK et al (2008) Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 27:80–89
20. Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ (2009) Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol 44:6–14
21. Petta S, Eslam M, Valenti L et al (2017) Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int 37:1389–1396
22. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P (2015) Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47:181–190
23. Shen J, Wong GL, Chan HL et al (2014) PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 39:532–539
24. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:330–344
25. Yki-Järvinen H (2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diab Endocrinol 2:901–910
26. Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121–129
27. Glass LM, Dickson RC, Anderson JC et al (2015) Total body weight loss of >/= 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60:1024–1030
28. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–378 e365; quiz e314–365
29. Houghton D, Thoma C, Hallsworth K et al (2017) Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol 15:96–102 e103
30. Ratziu V (2017) Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int 37(Suppl 1):90–96
31. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD (2017) Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. Metabolism 68:119–132
32. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20:953–966
33. American Diabetes Association (2017) Standards of medical care in diabetes-2017. Diabetes Care 40:S64-S74
34. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 55:1577–1596
35. Marchesini G, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358:893–894
36. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP (2004) Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20:23–28
37. Uygun A, Kadayifci A, Isik AT et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537–544
38. Schields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ (2009) The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Ther Adv Gastroenterol 2:157–163
39. Loomba R, Lutchman G, Kleiner DE et al (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29:172–182
40. Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–1090
41. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307
42. Aithal GP, Thomas JA, Kaye PV et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176–1184
43. Sanyal AJ, Chalasani N, Kowdley KW et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685
44. Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165:305–315
45. Idilman R, Mizrak D, Corapcioglu D et al (2008) Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28:200–208
46. Ratziu V, Giral P, Jacqueminet S et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 135:100–110
47. Ratziu V, Charlotte F, Bernhardt C et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51:445–453
48. Torres DM, Jones FJ, Shaw JC et al (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54:1631–1639
49. Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690
50. Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of vitamin E orMetformin for treatment of nonalcoholic fatty liver disease in children and adolescents the TONIC randomized controlled trial. JAMA 305:1659–1668
51. Chen HP, Shieh JJ, Chang CC et al (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606–615
52. Bhat A, Sebastiani G, Bhat M (2015) Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol 7:1652–1659
53. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
54. Targher G, Bertolini L, Padovani R et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218
55. Grygiel-Górniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J 13:17
56. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
57. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone. Hepatology 38:1008–1017
58. Omer Z, Cetinkalp S, Akyildiz M et al (2010) Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 22:18–23
59. Promrat K, Lutchman G, Uwaifo GI et al (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196
60. Lutchman G, Modi A, Kleiner DE et al (2007) The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46:424–429
61. Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177:633–640
62. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus a meta-analysis of randomized trials. JAMA 298:1180–1188
63. Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370:1129–1136
64. Jain MR, Giri SR, Bhoi B et al., 75th Scientific Session - ADA, June 5–9, 2015 • Boston, MA, USA Saroglitazar Shows Therapeutic Benefits in Mouse Model of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). Poster
65. Jain MR, Giri SR, Trivedi C et al (2015) Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect 3:e00136
66. Pai V, Paneerselvam A, Mukhopadhyay S et al (2014) A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 8:132–141
67. Ratziu V, Harrison SA, Francque S et al (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150:1147–1159 e1145
68. Lee YH, Kim JH, Kim SR et al (2017) Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci 32:60–69
69. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157
70. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
71. Rizvi AA, Patti AM, Giglio RV et al (2015) Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther 15:1391–1397
72. McAdam-Marx C, Nguyen H, Schauerhamer MB et al (2016) Glycemic control and weight outcomes for Exenatide once weekly versus Liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis. Clin Ther 38:2642–2651
73. Armstrong MJ, Houlihan DD, Rowe IA et al (2013) Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 37:234–242
74. Petit JM, Cercueil JP, Loffroy R et al (2017) Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study. J Clin Endocrinol Metab 102:407–415
75. Tang A, Rabasa-Lhoret R, Castel H et al (2015) Effects of insulin glargine and Liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 38:1339–1346
76. Smits MM, Tonneijck L, Muskiet MH et al (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 59:2588–2593
77. Armstrong MJ, Hull D, Guo K et al (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64:399–408
78. Sathyanarayana P, Jogi M, Muthupillai R et al (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19:2310–2315
79. Shao N, Kuang HY, Hao M et al (2014) Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 30:521–529
80. Dutour A, Abdesselam I, Ancel P et al (2016) Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18:882–891
81. Kenny PR, Brady DE, Torres DM et al (2010) Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105:2707–2709
82. Gluud LL, Knop FK, Vilsboll T (2014) Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open 4:e005325
83. Seko Y, Sumida Y, Tanaka S et al (2016) Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47:1206–1211
84. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
85. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
86. White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
87. Shirakawa J, Fujii K, Ohnuma K et al (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diab Metab Syndr 60:1246–1257
88. Jung YA, Choi YK, Jung GS et al (2014) Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract 105:47–57
89. Yilmaz Y, Yonal O, Deyneli O et al (2012) Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 75:240–244
90. Joy TR, McKenzie CA, Tirona RG et al (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol 23:141–150
91. Cui J, Philo L, Nguyen P et al (2016) Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65:369–376
92. Kato H, Nagai Y, Ohta A et al (2015) Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract 109:199–205
93. Macauley M, Hollingsworth KG, Smith FE et al (2015) Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 100:1578–1585
94. Mashitani T, Noguchi R, Okura Y et al (2016) Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 4:183–187
95. Chao EC, Henry RR (2010) SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 9:551–559
96. Trujillo JM, Nuffer WA (2017) Impact of sodium-glucose cotransporter 2 inhibitors on Nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy 37:481–491
97. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
98. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334
99. Nakano S, Katsuno K, Isaji M et al (2015) Remogliflozin Etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol 5:190–198
100. Jojima T, Tomotsune T, Iijima T et al (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8:45
101. Qiang S, Nakatsu Y, Seno Y et al (2015) Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 7:104
102. Komiya C, Tsuchiya K, Shiba K et al (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11:e0151511
103. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582–2592
104. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223–2233
105. Fadini GP, Avogaro A (2017) SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diab Endocrinol 5:680–681
106. Yamagishi S, Nakamura K, Inoue H (2005) Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). Med Hypotheses 65:377–379
107. Nozaki Y, Fujita K, Yoneda M et al (2009) Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 51:548–556
108. Rudovich NN, Weickert MO, Machann J, Pfeiffer AFH (2010) Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? J Hepatol 52:951–954
109. Carrascosa M, Pascual F, Aresti S (1997) Acarbose-induced acute severe hepatotoxicity. Lancet 349:698–699
110. Gentile S, Turco S, Guarino G et al (1999) Non-insulin-dependent diabetes mellitus associated with nonalcoholic livercirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose. Ann Ital Med Int 14:7–14
111. Chiasson JJR, Gomis R, Hanefeld M, Karasik A, Laasko M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDMTrial. JAMA 290:486–494
112. Jil M, Rajnikant M, Richard D, Iskandar I (2017) The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a retrospective cohort study. Diab Vasc Dis Res 14:295–303
113. Nystrom T, Bodegard J, Nathanson D et al (2017) Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 123:199–208
114. Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:1038–1048
115. Lazaridis N, Tsochatzis E (2017) Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol 11:357–369
116. Lombardi R, Onali S, Thorburn D et al., 2017 Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 1–183
117. Wong CR, Nguyen MH, Lim JK (2016) Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 22:8294–8303